ISRCTN31053647 https://doi.org/10.1186/ISRCTN31053647

Doxycycline Plus Streptomycin Versus Ciprofloxacin Plus Rifampicin in Spinal Brucellosis

Submission date	Recruitment status	[_] Prospectively registered
22/03/2006	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
29/03/2006	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
13/10/2009	Infections and Infestations	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Emine Alp

Contact details
Department of Infectious Disease
Erciyes University Medical School
Kayseri
Türkiye
38039
ealp@erciyes.edu.tr

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
04/131

Study information

Scientific Title

Study objectives
Ciprofloxacin plus rifampicin may be an alternative treatment regimen to doxycycline plus streptomycin in the treatment of spinal brucellosis

Ethics approval required
Old ethics approval format

Ethics approval(s)
Yes, Approved by the Ethical Committee of Erciyes University, approval date: 4/05/2001, reference number: 04/131

Study design
An open, controlled and non-randomized trial

Primary study design
Interventional

Secondary study design
Non randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Brucellosis is an infectious disease affecting multiple systems including vertebrae

Interventions
To compare the efficacy, adverse drug reactions, complications and cost of ciprofloxacin plus rifampicin versus doxycycline plus streptomycin in the treatment of spinal brucellosis

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Doxycycline, streptomycin, ciprofloxacin, rifampicin

Primary outcome measure

1. Clinical efficacy of ciprofloxacin plus rifampicin in spinal brucellosis
2. The prevalence of relapses

Secondary outcome measures
The cost of the two regimens

Overall study start date
01/01/2002

Completion date
31/12/2004

Eligibility

Key inclusion criteria
The patients diagnosed with spinal brucellosis between January 2002 to December 2004 were enrolled into two study groups consecutively

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
31 patients

Key exclusion criteria
1. Age less than 16 years
2. Pregnancy
3. Neurobrucellosis
4. Previous history of brucellosis and antimicrobial therapy and discontinuation of the therapy for any reason (allergy to any of the drugs, death, adverse reactions)

Date of first enrolment
01/01/2002

Date of final enrolment
31/12/2004

Locations

Countries of recruitment
Türkiye

Study participating centre
Department of Infectious Disease
Kayseri
Türkiye
38039

Sponsor information

Organisation
Erciyes University Medical School (Turkey)

Sponsor details
Department of Infectious Disease
Erciyes University Medical School
Kayseri
Türkiye
38039
ealp@erciyes.edu.tr

Sponsor type
University/education

ROR
https://ror.org/047g8vk19

Funder(s)

Funder type
University/education

Funder Name
The study was supported by Infectious Disease Clinic, Erciyes University Medical School (Turkey)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	11/04/2006		Yes	No